Tirzepatide

Tirzepatide is a dual GIP and GLP-1 receptor agonist that has become one of the most studied metabolic peptides in recent pharmaceutical history. Approved by the FDA in May 2022 under the name Mounjaro for type 2 diabetes, and subsequently approved in November 2023 as Zepbound for chronic weight management, tirzepatide represents a meaningful shift in how researchers and clinicians approach metabolic disease. The compound is a 39-amino-acid synthetic peptide that was engineered to mimic and co-activate two distinct incretin hormones simultaneously — something no approved drug had achieved before its arrival.

Researchers became interested in the dual incretin approach because GIP and GLP-1 have overlapping but complementary roles in metabolic regulation. GLP-1 receptor agonists such as semaglutide had already demonstrated strong efficacy for diabetes and weight loss, but scientists at Eli Lilly hypothesized that adding GIP receptor activity could amplify those effects. The resulting molecule, tirzepatide, was designed with a fatty acid modification that extends its half-life to approximately five days, making once-weekly dosing practical.

What makes tirzepatide particularly interesting to researchers is the magnitude of the weight loss it produces. In the SURMOUNT-1 trial published in the New England Journal of Medicine in 2022, participants without diabetes achieved average body weight reductions of up to 22.5% over 72 weeks at the highest dose — a figure that rivaled outcomes seen with bariatric surgery in some comparisons. This placed tirzepatide ahead of all previously approved non-surgical weight loss treatments in terms of efficacy.

Beyond diabetes and obesity, researchers have begun investigating tirzepatide in metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver disease driven by excess fat accumulation. A 2024 New England Journal of Medicine study found meaningful improvements in liver fibrosis with tirzepatide treatment. Cardiovascular outcomes research is also underway, with the SURPASS-CVOT trial comparing tirzepatide against the GLP-1 agonist dulaglutide in patients with type 2 diabetes and established cardiovascular disease. Results from that trial published in 2025 showed significant reductions in major adverse cardiovascular events, adding to the compound's clinical profile.

Tirzepatide exerts its effects through simultaneous agonism at two G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Both receptors are expressed in the pancreatic beta cells, brain, adipose tissue, and gastrointestinal tract, and both play key roles in postprandial metabolic signaling.

At the GLP-1 receptor, tirzepatide mimics the actions of endogenous GLP-1, a hormone released from intestinal L-cells in response to food intake. GLP-1R activation in pancreatic beta cells stimulates glucose-dependent insulin secretion, meaning it increases insulin release only when blood glucose is elevated — a mechanism that substantially reduces the risk of hypoglycemia compared to older insulin secretagogues. GLP-1R signaling also suppresses glucagon release from pancreatic alpha cells, slows gastric emptying, and activates satiety centers in the hypothalamus and brainstem, reducing overall food intake.

At the GIP receptor, tirzepatide engages a pathway that was historically considered less therapeutically useful because GIP-based agents alone showed modest effects in people with type 2 diabetes. However, research has suggested that GIPR agonism in the context of concurrent GLP-1R activation produces synergistic effects on weight loss and insulin sensitivity. GIPR is expressed in adipocytes and the central nervous system, and activation of this receptor appears to enhance fat metabolism and amplify the anorectic effects of GLP-1R signaling. A 2022 review in the International Journal of Molecular Sciences highlighted that the dual mechanism may rebalance energy homeostasis through both central appetite suppression and peripheral lipid metabolism.

Tirzepatide is structurally based on the native GIP sequence but incorporates a C20 fatty diacid moiety attached via a linker, which enables binding to albumin in the bloodstream. This albumin binding extends the peptide's plasma half-life to approximately five days and reduces enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), supporting once-weekly subcutaneous administration. The molecule's balanced affinity for both receptors — rather than strong preference for one — appears important to its clinical profile, though the precise contribution of each receptor to observed outcomes continues to be an active area of study.

Tirzepatide has accumulated one of the largest and most rapidly growing clinical evidence bases of any peptide drug in recent years, with key findings published across high-impact journals including the New England Journal of Medicine, JAMA, and The Lancet.

The foundational phase 3 diabetes trial, SURPASS-1, published in The Lancet in July 2021, enrolled 478 adults with type 2 diabetes inadequately controlled on diet and exercise alone. Participants receiving tirzepatide at 5, 10, or 15 mg once weekly achieved HbA1c reductions of 1.87%, 1.89%, and 2.07% respectively, compared with 0.04% for placebo — with 31% to 52% of participants reaching normal glycemic levels.

A pivotal head-to-head trial published in the New England Journal of Medicine in August 2021 (SURPASS-2) compared tirzepatide directly against semaglutide 1 mg once weekly in 1,879 people with type 2 diabetes. Tirzepatide at all three doses outperformed semaglutide on both HbA1c reduction and body weight loss, with tirzepatide 15 mg producing an average weight reduction of 12.4 kg versus 6.2 kg with semaglutide.

For obesity specifically, a 2024 retrospective cohort study published in JAMA Internal Medicine compared real-world weight loss outcomes for semaglutide and tirzepatide in 41,222 adults with overweight or obesity and no diabetes. Tirzepatide users were significantly more likely to achieve 5%, 10%, and 15% body weight reductions at both 3 and 6 months, with tirzepatide showing statistically superior outcomes across all thresholds. A subsequent 2025 randomized trial published in the New England Journal of Medicine (PMID 40353578) also found tirzepatide superior to semaglutide for weight loss in people with obesity.

The SURMOUNT-4 trial, published in JAMA in January 2024, examined what happens when tirzepatide is stopped after an initial weight loss period. Among 670 participants who had already lost weight during a 36-week open-label lead-in phase, those switched to placebo regained an average of 14% of body weight over 52 weeks, while those who continued tirzepatide lost an additional 5.5%. This underscored the need for continued treatment to maintain weight loss outcomes.

In liver disease research, a 2024 New England Journal of Medicine study investigated tirzepatide in 190 adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced liver fibrosis. At 52 weeks, MASH resolution was achieved in 62.4% of participants receiving tirzepatide 10 mg compared with 10% receiving placebo — a striking difference that has accelerated interest in the drug as a potential treatment for NASH/MASH.

Cardiovascular outcome data arrived in 2025, when the SURPASS-CVOT trial results were published in the New England Journal of Medicine. The trial compared tirzepatide to dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. Tirzepatide produced a 17% relative reduction in major adverse cardiovascular events compared with dulaglutide, extending the drug's clinical value beyond metabolic control alone. Additionally, SURPASS-5, published in JAMA in 2022, showed that adding tirzepatide to insulin glargine produced HbA1c reductions of 1.24% to 1.47% compared with 0.86% for placebo, without increasing severe hypoglycemia risk.

In completed phase 3 clinical trials, tirzepatide was studied at doses of 5 mg, 10 mg, and 15 mg administered once weekly via subcutaneous injection. Dose escalation protocols were used to improve tolerability: trials typically started participants at 2.5 mg once weekly and increased the dose by 2.5 mg increments every four weeks until the target dose was reached. The FDA-approved dosing for type 2 diabetes (Mounjaro) follows this escalation schedule starting at 2.5 mg and reaching a maximum of 15 mg. The same escalation and dose range applies to the obesity indication (Zepbound). Doses used across the major SURPASS and SURMOUNT trial programs were 5 mg, 10 mg, and 15 mg as the maintenance doses, with these three arms consistently included in phase 3 studies.

Tirzepatide's safety profile is among the best characterized of any recently approved peptide drug, given the size and scope of its phase 3 trial program. Across the SURPASS and SURMOUNT trials, gastrointestinal adverse events were the most frequently reported side effects. Nausea occurred in 17% to 40% of participants depending on dose, diarrhea in 13% to 23%, and vomiting in 6% to 13%. These effects were generally mild to moderate in severity and most common during dose escalation periods, with rates declining over time as patients adjusted to higher doses.

Discontinuation due to adverse events occurred in approximately 5% to 10% of participants across trials, with gastrointestinal symptoms being the primary reason. The gradual dose escalation protocol used in all major trials was specifically designed to reduce the incidence and severity of these effects.

Pancreatitis is a theoretically relevant concern for any GLP-1 receptor agonist, given the role of GLP-1 signaling in pancreatic function. The clinical trials reported low rates of acute pancreatitis, but because the absolute incidence was small, definitive conclusions about causality require ongoing postmarket surveillance. Tirzepatide carries an FDA boxed warning for thyroid C-cell tumors based on findings in rodent carcinogenicity studies, where GLP-1 receptor agonists were found to cause thyroid tumors. This risk has not been observed in humans, and tirzepatide is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Hypoglycemia risk was low when tirzepatide was used as monotherapy or without insulin. However, in the SURPASS-5 trial, which added tirzepatide to insulin glargine, hypoglycemia rates were higher than placebo, requiring insulin dose reductions in many participants.

Gallbladder-related events, including cholelithiasis (gallstones), were reported more frequently in tirzepatide-treated participants than placebo, consistent with patterns seen across GLP-1 receptor agonist drug class. Rapid weight loss is a known risk factor for gallstone formation, which likely contributes to this signal. Long-term cardiovascular and renal safety data are accumulating, and the 2025 SURPASS-CVOT results were reassuring, showing no excess cardiovascular harm and a significant reduction in events versus an active comparator.

Tirzepatide holds FDA approval for two indications: type 2 diabetes (Mounjaro, approved May 2022) and chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity (Zepbound, approved November 2023). Active research is investigating its potential in metabolic dysfunction-associated steatohepatitis (MASH), where a phase 3 trial is underway following promising phase 2 data published in 2024. The SURPASS-CVOT cardiovascular outcomes trial published results in 2025 confirming a reduction in major adverse cardiovascular events versus dulaglutide. Researchers are also studying tirzepatide in obstructive sleep apnea, heart failure with preserved ejection fraction, and chronic kidney disease. A key remaining gap is long-term safety data beyond three years, as the longest trials ran approximately 88 weeks. Comparative effectiveness against other GLP-1 agonists in head-to-head randomized trials is also an evolving area, with the first prospective randomized comparison against semaglutide published in 2025.